Epithalon Dosage and Protocol in the Research Literature

Epithalon Research Dosage Ranges

Published Epithalon dosage varies by study type, species, and endpoint. The Epithalon dosage in the research literature spans the following documented ranges.

In rodent longevity studies: 1.0 μg/mouse subcutaneous, administered on 5 consecutive days per month from age 3 months to death in female SHR mice ^[4]. In senescence-accelerated SAMP-1 mice, the same monthly protocol used 1 μg/mouse, 5 times per week ^[14]. In C3H/He female mice, a longer-duration oncostatic protocol used 0.1 μg/mouse, 5 times per week — a 10-fold lower per-administration dose over a more extended schedule ^[16].

In Drosophila lifespan studies: extremely low dietary concentrations at the larval stage — 0.001 to 5 × 10⁻⁶ wt.% of culture medium — produced 11–16% lifespan extension ^[3]. The effective concentration range was 16,000–80,000,000 times lower than melatonin for comparable effect.

In human cell-line studies: 0.1, 0.2, 0.5, and 1.0 μg/mL in in vitro culture medium across three weeks ^[2]. In retinal epithelial cell cultures: 20, 40, and 60 ng/mL ^[15].

In the retinitis pigmentosa clinical series: 5.0 μg parabulbar (para-ocular) injection for 10 consecutive days in 162 patients ^[8]. This is the only published human dose figure tied to a clinical endpoint and a defined protocol.

No standard or consensus Epithalon dosage for humans has been established in any regulatory or peer-reviewed framework.

Epithalon Protocol

The Epithalon research protocol used in the most-cited longevity studies follows a monthly cycled schedule: 5 consecutive days of subcutaneous administration per month, beginning in early adulthood and continuing through the lifespan of the animal ^[4][14]. This is the Anisimov-group rodent protocol, not a human treatment protocol.

The retinitis pigmentosa clinical series used a simpler 10-consecutive-day parabulbar course without cycling ^[8]. Earlier Epithalamin studies in elderly human subjects used unspecified dosing for neuroendocrine normalization endpoints ^[6][7] — precise dose and schedule are not published in those papers.

How long is the Epithalon cycle? In the published rodent longevity studies, the cycle is 5 days per month, repeated monthly over the animal's lifespan — effectively continuous cycling ^[4][14]. In the retinitis pigmentosa human series, the cycle was a single 10-day consecutive course ^[8]. The 2025 Araj review notes that Russian-origin commercial protocols often describe 10–20 day cycles repeated 1–2 times per year, but peer-reviewed publication of those specific human schedules is not available ^[17].

How long does Epithalon take to work in research models? In cell-line studies, telomerase activity and hTERT expression were detectable within days at in vitro concentrations ^[1][2]. Circadian normalization effects in animal models appeared within weeks of initiating the protocol ^[5][7]. Human timing data outside the retinitis pigmentosa clinical series is not published.

Routes Studied

The documented routes of Epithalon administration in published research are: subcutaneous injection (primary route in rodent longevity and oncostatic studies ^[4][14][16]), parabulbar injection (retinitis pigmentosa clinical series ^[8]), in vitro culture medium (cell-line studies ^[1][2][15]), and dietary administration in culture medium (Drosophila larval stage ^[3]).

Oral and sublingual routes are discussed in secondary literature and commercial contexts, but no peer-reviewed bioavailability study for oral Epithalon has been published. As a tetrapeptide with a molecular weight of ~390 Da, Epitalon is subject to gastrointestinal proteolysis — enzymatic degradation of short peptides in the digestive tract. Small peptides can in some cases cross intestinal epithelium; the Araj 2025 review notes oral routes are studied but formal bioavailability data are not published ^[17].

Subcutaneous injection has also been demonstrated to allow membrane penetration and nuclear entry in HeLa cells, which is relevant to the intracellular TERT gene upregulation mechanism ^[17]. The stability notes from the 2025 review indicate Epitalon contains intramolecular salt bridges that stabilize its structure and that it binds specifically to DNA sequences ATTTG and ATTTC — relevant to telomerase promoter regions.

Epitalon Half-Life and Pharmacokinetics

Formal Epitalon half-life and pharmacokinetics data in humans does not exist in the published literature. No validated human pharmacokinetic study has been published.

What is the half-life of Epitalon? As a short tetrapeptide (4 amino acids, MW ~390 Da), plasma clearance is expected to be rapid — estimated at approximately 30 minutes in some secondary sources, consistent with the enzymatic degradation kinetics of short peptides. No peer-reviewed measurement of this figure in humans has been published.

Two characteristics may complicate the simple fast-clearance picture. First, downstream effects — telomerase gene expression, melatonin normalization — are transcriptional and epigenetic changes that may persist beyond plasma clearance. The TERT upregulation observed in cell lines is a gene-expression change, not a pharmacodynamic effect that requires continuous peptide presence. Second, the DNA-binding specificity of AEDG (to sequences ATTTG and ATTTC in telomerase promoter regions) suggests nuclear localization may extend the effective duration of the peptide's action beyond what plasma half-life alone predicts.

In the absence of published pharmacokinetic data, any dose-frequency discussion for humans remains speculative. The rodent protocols (5 days per month ^[4][14]) and the retinitis pigmentosa protocol (10 consecutive days ^[8]) are the only schedules tied to clinical or experimental outcomes in the literature.